E-mail a Wiley Online Library Link

Sarah Sinclair and Sandra M. Swain Primary systemic chemotherapy for inflammatory breast cancer Cancer 116

Version of Record online: 19 MAY 2010 | DOI: 10.1002/cncr.25166

The addition of anthracyclines and taxanes to neoadjuvant chemotherapy regimens for inflammatory breast cancer (IBC) has improved survival compared with historical controls. Vascular endothelial growth factor, a promoter of angiogenesis, is highly expressed in IBC, making the angiogenesis pathway an attractive therapeutic target.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field